GSK plc Sponsored ADR (GSK)
GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug
Through the Boston Pharma deal, GSK aims to strengthen its pipeline, as some of its key products are nearing the end of their exclusivity period.
GSK splashes out $1.2bn up-front for liver treatment still in clinical trials
GSK PLC (LSE:GSK, NYSE:GSK) has struck a deal to acquire a drug to treat and prevent the progression of steatotic liver disease, poised for phase III clinical trials, for up to $2 billion. The disease affects up to 5% of the global population, the FTSE 100 group says, and is an "area of significant unmet medical need with limited treatment options".
GSK Buys Liver-Disease Treatment From Boston Pharmaceuticals for Up to $2 Billion
The pharma giant will pay $1.2 billion up-front for efimosfermin, with deal including potential success-based milestone payments of $800 million.
GSK to buy efimosfermin for up to $2 billion
British pharmaceutical giant GSK on Wednesday said it will buy efimosfermin, a phase III-ready potential specialty medicine from Boston Pharmaceuticals, for up to $2 billion.
ITeos, GSK discontinue lung cancer therapy development
iTeos Therapeutics and partner GSK said on Tuesday that they terminated the development of their experimental lung cancer therapy after its failure to significantly improve progression free survival in a mid-stage trial.
Glaxo (GSK) Upgraded to Buy: Here's What You Should Know
Glaxo (GSK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
5 Reasons GSK Looks Good
GSK's stock price has significantly outperformed the healthcare sector this year, supported by its healthy Q1 2025 numbers. Both turnover and EPS growth exceeded expectations, and the company's guidance indicates that the stock's forward P/E is competitive too. Additionally, GSK's medium-to-long-term financial prospects look good too, based on the company's latest outlook, which also works in the stock's favour.
Here's Why GSK (GSK) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
GSK Q1 Earnings Beat, Sales Lag, Stock Gains on Tariff Reassurance
GSK reports mixed first-quarter 2025 results. Shares rise in pre-market after it reaffirms guidance and says it is "well positioned" to handle the U.S. tariffs.
GSK plc (GSK) Q1 2025 Earnings Conference Call Transcript
GSK plc (NYSE:GSK ) Q1 2025 Earnings Conference Call April 30, 2025 7:00 AM ET Company Participants Constantin Fest - Head of IR Emma Walmsley - CEO Luke Miels - Chief Commercial Officer Julie Brown - CFO David Redfern - President Corporate Development Tony Wood - Chief Scientific Officer Conference Call Participants James Gordon - JP Morgan Kerry Holford - Berenberg Jo Walton - UBS Graham Parry - Bank of America Simon Baker - Redburn Rajan Sharma - Goldman Sachs Sarita Kapila - Morgan Stanley Constantin Fest Ladies and gentlemen, a very warm welcome to this GSK Q1 2025 Results Call. My name is Constantin Fest, new head of IR at GSK, and I'm delighted to be joined today by Emma Walmsley, Luke Miels and Julie Brown.
Here's Why GSK (GSK) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
GSK Posts Strong Results, Says 'Well Positioned' in Case of Pharma Tariffs
U.S.-listed shares of GSK (GSK) are gaining in premarket trading Wednesday after the British pharma giant posted better-than-expected first-quarter results and said it was "well positioned" should the Trump administration imposes tariffs against the industry.
